UBS raised the firm’s price target on Teva (TEVA) to $30 from $28 and keeps a Buy rating on the shares. Teva, one of the firm’s top picks for ...
Teva Pharmaceuticals USA Inc. is taking the Biden administration to court over its drug price negotiation program, days ...
Teva Pharmaceuticals is suing the Centers for Medicare & Medicaid Services (CMS) for its implementation of the drug price ...
The Delaware Supreme Court affirmed Friday a trial court’s decision in favor of Teva Pharmaceutical Industries Ltd.'s US unit ...
The following is a summary of “Industry Payments and Branded Glatiramer Acetate Prescribing in the US Medicare Program,” ...
Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory ...
Teva Pharmaceuticals has announced a strategic ... which will be sold under the brand name AHZANTIVE®, pending regulatory approval. Klinge, which holds the global commercialization rights ...
Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to ...
Teva Pharmaceuticals challenges the Inflation Reduction Act, arguing CMS's drug pricing policies harm generics, biosimilars, ...
FDA issues new warnings about rare but severe allergic reactions, including anaphylaxis, linked to MS drug glatiramer acetate, urging immediate medical attention.
Teva was established as the European commercialisation partner of FYB201, Formycon's biosimilar to ranibizumab (Lucentis).
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback